Lipid Nanoparticle-Mediated RNA Delivery for Alzheimer’s Disease Therapy

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

Neurodegenerative disorders are frequently associated with persistent neuroinflammation, and Alzheimer’s disease (AD) is no exception. Chronic inflammation represents a central feature of AD pathology, driving disease progression and contributing to neuronal loss. Microglia, the most abundant immune cells in the brain, play a dual role: under normal conditions they remove cellular waste and provide neuroprotection, but in AD, their dysregulation promotes inflammatory signaling and accelerates pathology.

Recent genomic studies have revealed that microglia harbor AD-risk loci, specific genomic elements that may contribute to disease susceptibility. These discoveries open avenues for genetic and RNA-based therapeutic strategies aimed at modulating microglial activity. Among these, small interfering RNA (siRNA) has emerged as a promising modality for gene silencing in neurodegenerative disease models.

Challenges of RNA Delivery to the Brain

The therapeutic application of RNA technologies is limited by delivery barriers, most notably the blood-brain barrier (BBB). While RNA therapies have been tested across various diseases, including Parkinson’s disease, cancer, and AD, their translation to the central nervous system (CNS) requires specialized approaches for transfection.

Lipid nanoparticles (LNPs) have been developed as effective carriers for RNA molecules. These nanocarriers can encapsulate siRNA and promote cellular uptake, including in brain cells. Although intravenous delivery faces BBB restrictions, direct administration methods, such as intracisternal injection into the cisterna magna, have been shown to bypass this barrier. While invasive, this technique has demonstrated high efficiency and tolerability in preclinical studies.

PU.1 as a Therapeutic Target

One transcription factor of interest is PU.1, a key regulator of microglial function and a contributor to neuroinflammatory cascades. Elevated PU.1 activity has been linked to enhanced inflammatory gene expression and acceleration of AD pathology.

Targeting PU.1 with siRNA represents a potential disease-modifying approach. By inhibiting PU.1 expression, microglial inflammatory activity can be reduced, thereby limiting chronic neuroinflammation and slowing disease progression.

MG-LNP Platform for siRNA Delivery

A specialized lipid nanoparticle formulation, MG-LNP, has been developed to selectively deliver anti-PU.1 siRNA to microglia. Preclinical investigations in stem cell-derived microglia-like cells (iMGLs) and animal models have demonstrated that MG-LNPs can achieve over 90% transfection efficiency. Importantly, these nanoparticles show minimal toxicity while effectively suppressing PU.1 expression.

Beyond microglia, astrocytes—another glial population implicated in AD-related neuroinflammation—also internalize MG-LNPs, broadening the therapeutic impact. Treatment reduces cytokine release and inflammatory protein accumulation, both of which are associated with neuronal injury and cognitive decline.

Clinical Implications of PU.1 Silencing

Reducing PU.1 expression in microglia and astrocytes through siRNA delivery mitigates chronic neuroinflammation, a central driver of AD pathology. Experimental evidence indicates improvements in neuroprotection and potential preservation of cognitive function following PU.1 inhibition.

LNP-based RNA delivery systems are advantageous because they exhibit high cellular uptake, low toxicity, and can be engineered for targeted delivery. These features make them a competitive platform for addressing neurodegenerative disorders.

Future Directions

While preclinical results are promising, further investigation is required to assess long-term efficacy, optimize dosing strategies, and evaluate safety in human trials. Moreover, expanding this approach to multitargeting strategies could enhance therapeutic benefits by addressing multiple inflammatory and genetic drivers of AD simultaneously.

Conclusion

Lipid nanoparticle-mediated siRNA delivery represents an emerging therapeutic platform for Alzheimer’s disease. Targeting the PU.1 transcription factor in microglia and astrocytes demonstrates strong potential to reduce neuroinflammation and slow disease progression. As research advances, LNP-based RNA therapeutics may establish a new clinical paradigm in the treatment of neurodegenerative disorders.

REFERENCES

1. Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021). The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory.Iscience, 24(12).
2. Novikova, G., Kapoor, M., Tcw, J., Abud, E. M., Efthymiou, A. G., Chen, S. X., … & Goate, A. M. (2021). Integration of Alzheimer’s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes.Nature communications, 12(1), 1610.
3. Ralvenius, W. T., Andresen, J. L., Huston, M. M., Penney, J., Bonner, J. M., Fenton, O. S., … & Tsai, L. H. (2023). Nanoparticle‐mediated delivery of Anti‐PU. One siRNA via localized intracisternal administration reduces neuroinflammation.Advanced Materials, 2309225.
4. Rungta, R. L., Choi, H. B., Lin, P. J., Ko, R. W., Ashby, D., Nair, J., … & MacVicar, B. A. (2013). Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain.Molecular therapy. Nucleic acids, 2(12), e136.
5. Rungta, R. L., Choi, H. B., Lin, P. J., Ko, R. W., Ashby, D., Nair, J., … & MacVicar, B. A. (2013). Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain.Molecular therapy. Nucleic acids, 2(12), e136.
6. Rustenhoven, J., Smith, A. M., Smyth, L. C., Jansson, D., Scotter, E. L., Swanson, M. E., … & Dragunow, M. (2018). PU. 1 regulates Alzheimer’s disease-associated genes in primary human microglia.Molecular neurodegeneration, 13(1), 1-16.
7. Tsakiri, M., Zivko, C., Demetzos, C., & Mahairaki, V. (2022). Lipid-based nanoparticles and RNA as innovative neuro-therapeutics.Frontiers in Pharmacology, 13, 900610.
8. Tuma, J., Chen, Y. J., Collins, M. G., Paul, A., Li, J., Han, H., … & Lee, H. Y. (2023). Lipid nanoparticles deliver mRNA to the brain after an intracerebral injection.Biochemistry, 62(24), 3533-3547.